UNASSIGNED: Use of @entity575 nanoparticles (AgNPs) for their antimicrobial properties is widespread. Much of the previous work on the @entity137 of AgNPs has been conducted in vitro or following oral or intravenous administration in vivo. Intranasal (IN) instillation of AgNPs mimics inhalation exposure and allows further exploration of the @entity137 of these particles via respiratory tract exposure. The present study involved 1) single-dose exposures to assess tissue distribution and @entity137 and 2) repeated exposures to assess behavioral effects of IN AgNP exposure (nominally uncoated 25nm AgNP). AgNP deposition was localized in the liver, gut-associated lymphoid tissue, and brain. Decrease cellularity in spleen follicles was observed in treated @entity19 , along with changes in cell number and populations in the spleen. The splenic @entity6172 : @entity9492 ratio was also reduced following AgNP exposure. Expression of the oxidative stress-responsive gene @entity10183 was elevated in the hippocampus, but not cortex of treated @entity19 , as was the level of @entity10183 protein. @entity19 receiving 7days of IN exposure to 50mg/kg AgNPs exhibited similar learning- and memory-related behaviors to control @entity19 , except that treated @entity19 spent significantly less time in the target quadrant of the Morris Water Maze during the acquisition phase probe trial. These findings indicate systemic distribution and @entity137 following IN administration of AgNPs.

Systemic and behavioral effects of intranasal administration of XXXX nanoparticles.

@entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity9492 :: ('MESH:D019803', 'Chemical') :: ['GSSG'] @entity575 :: ('MESH:D012834', 'Chemical') :: ['silver'] @entity19 :: ('10090', 'Species') :: ['mice', 'Mice'] @entity6172 :: ('D005978', 'Chemical') :: ['GSH'] @entity10183 :: ('15368(Tax:10090)', 'Gene') :: ['HMOX1', 'Hmox1']
@entity575 :: (MESH:D012834,Chemical) :: ['silver']
